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ABSTRACT
Introduction. The disease-free interval (DFI) between
resection of primary colorectal cancer (CRC) and diagnosis
of liver metastases is considered an important prognostic
indicator; however, recent analyses in metastatic CRC
found limited evidence to support this notion.
Objective. The current study aims to determine the
prognostic value of the DFI in patients with
resectable colorectal liver metastases (CRLM).
Methods. Patients undergoing first surgical treatment of
CRLM at three academic centers in The Netherlands were
eligible for inclusion. The DFI was defined as the time
between resection of CRC and detection of CRLM. Base-
line characteristics and Kaplan–Meier survival estimates
were stratified by DFI. Cox regression analyses were per-
formed for overall (OS) and disease-free survival (DFS),
with the DFI entered as a continuous measure using a
restricted cubic spline function with three knots.
Results. In total, 1374 patients were included. Patients
with a shorter DFI more often had lymph node involvement
of the primary, more frequently received neoadjuvant
chemotherapy for CRLM, and had higher number of
CRLM at diagnosis. The DFI significantly contributed to
DFS prediction (p =0.002), but not for predicting OS
(p =0.169). Point estimates of the hazard ratio (95% con-
fidence interval) for a DFI of 0 versus 12 months and 0
versus 24 months were 1.284 (1.114–1.480) and 1.444
(1.180–1.766), respectively, for DFS, and 1.111
(0.928–1.330) and 1.202 (0.933–1.550), respectively, for
OS.
Conclusion. The DFI is of prognostic value for predicting
disease recurrence following surgical treatment of CRLM,
but not for predicting OS outcomes.
The liver remains the most frequent metastatic site for
patients with colorectal cancer (CRC), with approximately
30–40% of all patients diagnosed with CRC developing
colorectal liver metastases (CRLM) over the course of their
disease.1–4 Curatively intended treatment of CRLM has
increasingly been performed for more advanced disease,
with surgical resection being the mainstay of treatment.5
This is in part due to increasing local and systemic treat-
ment options (e.g. ablative therapies and preoperative
chemotherapy), and more extensive (multistaged) surgical
strategies (e.g. two-staged hepatectomies, Associating
Liver Partition and Portal vein ligation for Staged hepate-
ctomy [ALPPS], and the liver-first approach).3,6–13 Despite
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these advancements over time, there still remains room for
improvement, with most studies reporting 5-year overall
survival (OS) rates of 40–60%.10,14,15
Multiple clinical risk scores have been proposed to
predict survival outcomes after surgical treatment for
CRLM.16–20 The disease-free interval (DFI), defined as the
time between resection of the primary malignancy and the
diagnosis of CRLM, is considered a predictor of tumor
biology and prognosis. Recent analysis of the German
population-based case–control DACHS study found no
noticeable predictive value of the time to metastases on
survival outcomes in CRC patients.21 The analysis was
performed in 1027 patients diagnosed with CRC who
developed metastatic disease or had synchronous meta-
static disease at the time of CRC diagnosis. The authors did
not distinguish between type of metastatic disease or
whether patients were eligible for curative local therapy.
Therefore, the aim of the present study was to assess the
prognostic value of the DFI, specifically in patients with
CRLM eligible for surgical treatment.
METHODS
The current study was approved by the Medical Ethics
Committee of the Erasmus Medical Center (MEC-2018-
1743).
Patient Selection
All consecutive patients undergoing surgical treatment
for CRLM at the Erasmus MC Cancer Institute between
January 2000 and December 2016, at the Radboud
University Medical Center between July 2000 and June
2018, and at the Academic Medical Center of the Ams-
terdam UMC between November 2006 and September
2015 were eligible for inclusion. Patients with extrahepatic
disease at the time of surgery, as well as patients under-
going treatment for recurrent CRLM, were excluded. In
addition, the DFI had to be known and patients had to be
considered tumor-free following surgery for CRLM, or
following resection of the primary malignancy in case of a
liver-first approach.
Data Collection and Definitions
Patient data and clinicopathological characteristics of
the primary malignancy and CRLM were extracted from
prospectively maintained databases. The DFI was defined
as the time interval (months) between resection of the
primary colorectal malignancy and detection of CRLM.
The date of detection of CRLM was defined as the date of
medical imaging on which metastasis was first diagnosed.
The DFI of patients in whom CRLM were diagnosed prior
to or simultaneously with the primary CRC was considered
zero. OS was defined as the interval between surgery for
CRLM and death, while disease-free survival (DFS) was
defined as the interval between surgical treatment of hep-
atic metastasis and date of diagnosis of disease recurrence
or death. In case of absent recurrent disease or death,
patients were censored at the date of last follow-up.
Treatment and Follow-Up of Patients with Colorectal
Liver Metastases
All three participating centers are tertiary referral cen-
ters for liver surgery. A multidisciplinary tumor board
evaluates all patients referred for treatment of CRLM, to
establish optimal treatment strategy. In The Netherlands,
perioperative chemotherapy for CRLM is not considered
standard of care. In case of marginally resectable disease,
preoperative chemotherapy (oxaliplatin- or irinotecan-
based) is utilized in an effort to increase resectability and
optimize surgical treatment options. Follow-up of patients
after surgical treatment of CRLM is performed for up to
5 years according to Dutch guidelines. Serial carcinoem-
bryonic antigen (CEA) measurements are performed on a
3-monthly basis, while medical imaging by computed
tomography (CT) or magnetic resonance imaging (MRI) is
usually performed semi-annually for the first 2 years and
annually thereafter. The optimal treatment strategy for
recurrent disease is again determined by a multidisciplinary
tumor board. In case of liver-limited disease eligible for
local treatment with sufficient remnant liver volume, sal-
vage local therapy is generally attempted. In case of
concurrent oligometastasic extrahepatic disease, salvage
local treatment is still deemed feasible. In case of extra-
hepatic disease in more than one organ, salvage local
treatment is usually not pursued, but patients are treated
with palliative systemic therapy. Herein (repeat hepatic)
resections, ablations, and stereotactic radiotherapy are
considered local (i.e. curative intent) therapies. Yttrium-90
(Y90) radio embolization is not considered as curative
intent treatment and is only performed in case of progres-
sive liver-limited disease after first- and second-line
chemotherapy regimens. In general, Y90 radio emboliza-
tion is infrequently performed in The Netherlands.
Statistical Analysis
Categorical data are reported as counts with corre-
sponding percentages, and continuous data are reported as
median with corresponding interquartile range (IQR).
Baseline categorical and numerical variables were com-
pared using the Chi square and nonparametric Mann–
Whitney U or Kruskal–Wallis tests (depending on the
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number of strata), respectively. Kaplan–Meier survival
estimates were generated using the log-rank test to com-
pare across strata, and median follow-up for survivors was
determined using the reverse Kaplan–Meier method.
Baseline comparison and Kaplan–Meier OS and DFS
estimates were stratified by DFI (0–1, 2–12, 13–24,
and[ 24 months), and Cox multivariable regression
analysis for OS and DFS was performed. No stepwise
selection of predictors was applied. All variables consid-
ered for multivariable regression analysis comprised of
known clinical risk and treatment-related factors. With
regard to the resection margin in regression analysis,
patients treated solely with ablative therapy were consid-
ered R0. To allow for possible non-linear relationships, all
numerical and ordinal variables including the DFI were
entered continuously using restricted cubic spline functions
with three knots. Results were reported using the Wald
statistic for improvement of model fit for individual vari-
ables and their corresponding p value. The relative hazard
by DFI (months) on OS and DFS was graphically displayed
using partial effect plots. Due to the use of non-linear terms
(i.e. restricted cubic spline functions), no singular hazard
ratio (HR) with corresponding 95% confidence interval
(CI) for the DFI on OS and DFS can be given. Therefore,
point estimates of the HR and 95% CI for OS and DFS
were calculated for a DFI of 0 versus 12 months, 0 versus
24 months, 0 versus 36 months, and 0 versus 48 months,
respectively. To assess a possible effect of DFI on eligi-
bility for salvage local treatment, multivariable logistic
regression analysis on salvageable recurrence was per-
formed using restricted cubic spline functions with three
knots for all numerical or ordinal predictors. A partial
effect plot was used to graphically display the odds for
salvage local treatment by DFI (months). All statistical
analyses were performed using R version 3.5.1 (http://ww
w.r-project.org), and the R-package ‘rms’ was used to
perform regression analysis with restricted cubic spline
functions.
RESULTS
Between January 2000 and December 2016, a total of
840 eligible patients who underwent surgical treatment of
CRLM at the Erasmus MC Cancer Institute were identified.
Median follow-up for survivors was 67 months (IQR
37–111). During follow-up, disease recurrence was diag-
nosed in 568 (68%) patients and 416 (50%) patients died.
At the Radboud University Medical Center, 385 eligible
patients were operated on between July 2000 and June
2018. Median follow-up for survivors was 32 months (IQR
14–57). Disease recurrence was detected in 229 (59%)
patients and 96 (25%) patients died. From November 2006
to September 2015, a total of 149 eligible patients under-
went surgery at the Academic Medical Center. Median
follow-up for survivors was 54 months (IQR 29–78). Dis-
ease recurrence was diagnosed in 81 (54%) patients and 66
(44%) patients died during follow-up. In the combined
cohort of 1374 patients, the median follow-up for survivors
was 54 months (IQR 26–90).
Baseline characteristics stratified by DFI are reported in
Table 1. In general, patients with a shorter DFI were
younger, more often had a higher T stage and rate of lymph
node involvement of the primary tumor, more frequently
received neoadjuvant chemotherapy for CRLM, and had
more CRLM at diagnosis. Patients with a longer DFI more
often received adjuvant chemotherapy following CRC
resection and were found to have larger CRLM.
Kaplan–Meier survival curves for OS and DFS from
resection of CRLM stratified by DFI are shown in Fig. 1.
No overall or pairwise differences were found for OS
(overall p =0.692). For DFS, an overall significant differ-
ence between groups was found (p\0.001), with
individual comparisons showing a significant impaired
DFS for a DFI of 0–1 compared with 13–24 and[ 24
months (p =0.001 and p\0.001), and for a DFI of 2–12
compared with[ 24 months (p =0.008).
Results of multivariable regression models on OS and
DFS are reported in Table 2. No significant effect was
found for the DFI on OS (p =0.169). In multivariable
analysis for DFS, the DFI proved to be a significant pre-
dictor (p =0.002). Figure 2a shows the partial effect plots
of the relative hazard, with corresponding 95% confidence
band of the DFI (months). The relative hazard for DFI on
OS appears constant, while the relative hazard for devel-
oping a recurrence decreases as the DFI increases. This
decrease is seen for a DFI up to 24 months. These results
are reflected in the point estimates of the HR and 95% CI
for OS and DFS comparing a DFI of 0 versus 12 months, 0
versus 24 months, 0 versus 36 months, and 0 versus
48 months (Table 3).
Results of the multivariable analysis on the odds for
salvageable recurrence are reported in electronic sup-
plementary Table 1. Significant predictors found for
salvageable recurrence were location of the primary
tumor (p\0.001), CRC nodal status (p =0.011), and
preoperative CEA levels (p =0.028). The DFI did not
significantly contribute to the multivariable model pre-
diction (p =0.571). The partial effect plot in Fig. 2b
displays the odds, with corresponding 95% confidence
band, for a salvageable recurrence by the DFI (months).
The odds for a salvageable recurrence appear constant
over the DFI.
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TABLE 1 Baseline characteristics stratified by disease-free interval
Disease-free interval, months p value
0–1 [n = 682 (%a)] 2–12 [n = 297 (%a)] 13–24 [n = 211 (%a)] [ 24 [n = 184 (%a)]
Age at resection CRLM
(median [IQR])
64.0 [56.0–70.0] 65.0 [60.0–72.0] 67.0 [60.0–74.0] 67.5 [60.8–73.0] \ 0.001*
Sex
Female 257 (38) 106 (36) 70 (33) 57 (31) 0.315
Male 425 (62) 191 (64) 141 (67) 127 (69)
ASA classification
I–II 601 (89) 249 (85) 182 (87) 159 (89) 0.434
[ II 76 (11) 43 (15) 28 (13) 20 (11)
Missing 5 (1) 5 (2) 1 (0) 5 (3)
Primary tumor location
Left-sided 290 (43) 101 (35) 91 (44) 90 (50) 0.044*
Rectal 227 (34) 113 (39) 75 (36) 58 (32)
Right-sided 152 (23) 76 (26) 43 (21) 31 (17)
Missing 13 (2) 7 (2) 2 (1) 5 (3)
T stage
pT 0–2 106 (16) 61 (21) 50 (24) 43 (24) 0.011*
pT 3–4 565 (84) 231 (79) 158 (76) 138 (76)
Missing 11 (2) 5 (2) 3 (1) 3 (2)
N stage
N0 212 (32) 134 (46) 94 (45) 99 (55) \ 0.001*
N ? 457 (68) 160 (54) 113 (55) 82 (45)
Missing 13 (2) 3 (1) 4 (2) 3 (2)
Adjuvant CTx for CRC
No 568 (96) 175 (78) 108 (65) 105 (70) \ 0.001*
Yes 22 (4) 50 (22) 57 (35) 46 (30)
Missing 92 (13) 72 (24) 46 (22) 33 (18)
Neoadjuvant CTx for CRLM
No 243 (36) 211 (71) 169 (80) 140 (76) \ 0.001*
Yes 439 (64) 86 (29) 42 (20) 44 (24)
Number of CRLM (median [IQR]) 2.0 [1.0–4.0] 2.0 [1.0–3.0] 1.0 [1.0–2.0] 1.0 [1.0–2.0] \ 0.001*
Diameter of the largest CRLM
(median [IQR])
2.8 [1.9–4.1] 2.8 [2.0–4.0] 3.0 [2.0–4.1] 4.0 [2.6–5.5] \ 0.001*
Preoperative CEA (median [IQR]) 10.8 [3.6–44.3] 12.0 [3.9–34.8] 11.0 [4.3–27.8] 13.5 [5.2–33.4] 0.798
Resection margin CRLM
R0 581 (86) 261 (88) 178 (86) 155 (85) 0.730
R1 91 (14) 34 (12) 29 (14) 27 (15)
Missing 10 (1) 2 (1) 4 (2) 2 (1)
Clinical risk score
Low 269 (42) 178 (63) 187 (92) 171 (95) \ 0.001*
High 367 (58) 105 (37) 17 (8) 9 (5)
Missing 46 (7) 14 (5) 7 (3) 4 (2)
Hemihepatectomy
No 494 (73) 231 (78) 157 (74) 127 (69) 0.169
Yes 186 (27) 66 (22) 54 (26) 57 (31)
Missing 2 (0) 0 (0) 0 (0) 0 (0)
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DISCUSSION
The results of the current study show that patients with a
shorter DFI more often had high clinical risk characteris-
tics, such as nodal positive primaries, and more metastases
at the time of diagnosis. Despite the seemingly higher
clinical risk at baseline, the DFI was only found to be of
prognostic value for predicting disease recurrence, but not
for predicting OS.
This implies that patients with a shorter DFI develop
earlier disease recurrence that is not associated with
impaired OS. While this might be due to applied treatment
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FIG. 1 Kaplan–Meier survival curves for (a) overall survival and
(b) disease-free survival stratified by the disease-free interval
(months). The overall p value is displayed in the bottom right-hand
corner of each graph; p values of the pairwise comparison of
individual strata are reported in the left-hand corner; and the numbers
at risk per stratum are reported in the table below the graphs
TABLE 1 continued
Disease-free interval, months p value
0–1 [n = 682 (%a)] 2–12 [n = 297 (%a)] 13–24 [n = 211 (%a)] [ 24 [n = 184 (%a)]
Postoperative complications
None or grade 1–2 592 (87) 254 (86) 185 (89) 165 (90) 0.607
Grade 3 or higher 88 (13) 41 (14) 23 (11) 19 (10)
Missing 2 (0) 2 (1) 3 (1) 0 (0)
Postoperative mortality
No 672 (99) 289 (98) 207 (100) 181 (98) 0.362
Yes 9 (1) 7 (2) 1 (0) 3 (2)
Missing 1 (0) 1 (0) 3 (1) 0 (0)
CRLM colorectal liver metastases, IQR interquartile range, ASA American Society of Anesthesiologists, CTx chemotherapy, CRC colorectal
cancer, CEA carcinoembryonic antigen
aPercentages are expressed as proportions across each stratum (i.e. excluding ‘missing’). Percentages for ‘missing’ are expressed as a proportion
of missing values within each stratum
*a\ 0.05
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for recurrent disease, the current study showed that eligi-
bility for salvage local treatment was independent of the
DFI. These results appear contradictory to the general
hypothesis that time to cancer recurrence determines
prognosis. A possible explanation for this might be that it
matters less when disease recurrence occurs (or when it is
TABLE 2 Wald tests for improvement of multivariable Cox proportional hazard models fit for overall and disease-free survival
Overall survival Disease-free survival
Wald statistic p value Wald statistic p value
Age at resection of CRLM, yearsa 26.528 \ 0.001* 12.827 0.002*
Non-linear terms 1.441 0.230 1.62 0.203
Sex (male and female) 0.502 0.479 0.164 0.686
ASA classification (I–II and[ II) 1.729 0.189 0.644 0.422
Primary tumor location (left-sided, right-sided, and rectal) 7.064 0.029* 4.705 0.095
T stage (pT0–2 and pT3–4) 0.074 0.786 0.407 0.524
N stage (N0 and N ?) 16.345 \ 0.001* 25.479 \ 0.001*
Disease-free interval, monthsa 3.559 0.169 12.873 0.002*
Non-linear terms 0.168 0.682 7.315 0.007*
Number of CRLMa 13.105 0.001* 33.296 \ 0.001*
Non-linear terms 3.571 0.059 10.667 0.001*
Diameter of the largest CRLM, cma 17.171 \ 0.001* 6.267 0.044*
Non-linear terms 3.817 0.051 0.738 0.390
Preoperative CEA, lg/L 5.63 0.060 8.597 0.014*
Non-linear terms 5.427 0.020* 7.561 0.006*
Neoadjuvant chemotherapy (yes and no) 2.797 0.094 7.87 0.005*
Resection margin (R0 and R1) 6.542 0.011* 19.174 \ 0.001*
CRLM colorectal liver metastases, ASA American Society of Anesthesiologists, CEA carcinoembryonic antigen
aEntered as a continuous measure using a restricted cubic spline function with three knots
*a\ 0.05
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FIG. 2 (a) Partial effect plot of the relative hazard, with
corresponding 95% confidence band, of the DFI (months) on
disease-free and overall survival. (b) Partial effect plot of the odds
for salvageable recurrence, with corresponding 95% confidence band,
for the DFI (months). DFI disease-free interval
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diagnosed), but more whether it is eligible for salvage local
treatment that is most important for OS outcomes. The
current study found no difference in eligibility for salvage
local treatment between patients with a short or long DFI,
which could explain why OS was independent of the DFI.
While this might seem contradictory to common estab-
lished cancer theories, several studies have been performed
that support this hypothesis. The EORTC 40983 trial ran-
domized 364 patients between perioperative FOLFOX4
chemotherapy with surgery versus surgery alone for
resectable CRLM.22 The addition of chemotherapy pro-
longed progression-free survival in patients eligible for
surgery (p =0.035); however, long-term results showed that
the percentage of patients who eventually developed cancer
progression was equal: 130 (71%) in the surgery-only
group versus 124 (68%) in the perioperative chemotherapy
group. No difference in long-term OS was observed
(p =0.303), and no difference was found in the amount of
patients eligible for repeat resection (40 vs. 46%) or
radiotherapy (2 vs. 9%). This study therefore demonstrates
that perioperative chemotherapy seems to delay, but not
prevent, disease progression. The number of patients who
eventually develop progressive disease and the eligibility
for subsequent salvage treatment remains equal, therefore
no difference in OS is observed.
Similarly, with the addition of the recent COLOFOL
trial,23 15 randomized controlled trials evaluated a more
intensive versus a less intensive postoperative surveillance
after surgery for stage I–III CRC.24 Pooled meta-analysis
found that while intensive surveillance anticipates disease
recurrence, this does not translate into a cancer-specific
survival benefit.25 The three largest and most recent trials
had a combined sample size of 4939 patients,23,26,27 with
all three trials reporting no difference in OS outcomes.
Two of these trials reported on eligibility for salvage local
treatment, which was equal between the intensive and less
intensive surveillance groups.26,27 Intensive surveillance
allows us to detect disease recurrence earlier, but this does
not translate into a larger amount of people eligible for
local treatment, and thus no OS difference is achieved.
Repeat hepatic resection for recurrent CRLM has proven
feasible, and reported long-term survival outcomes are com-
parable with those after first surgical treatment.28–32 It would
therefore be interesting to assess the effect of the DFI between
hepatic resections on survival outcomes following second
liver resection for CRLM. The interval between CRLM sur-
gery and the date of hepatic recurrence has proven to be of
prognostic value in patients undergoing repeat hepatic resec-
tion.29 Patients with an interval of\ 6 months exhibited
impaired OS. While some studies reported similar results,31
others did not.30,32 In addition, retrospective analysis of such a
cohort is highly subject to selection bias. Clinical decision
making is largely influenced by the ‘known clinical risk fac-
tors’, of which this interval is generally considered to be one.
Therefore, interpretation of the prognostic value of the DFI
between hepatic resections should be done with caution until
reliable prospective data become available.
The results of the current study are insufficient to
denounce any prognostic value of the DFI on OS outcomes
after surgical treatment of CRLM. This study is limited in its
retrospective design. No data were available for the adher-
ence to follow-up scan protocols, which is an important
determinant of the DFS. In addition, lead time bias remains
an important potential confounder. It is possible that patients
with a shorter DFI are more often ineligible for surgical
treatment, or are considered unresectable during surgery.
Nevertheless, in those patients who actually undergo surgi-
cal treatment of CRLM, the DFI does not seem a strong
prognostic indicator for OS. These findings are in line with
the results reported by Rahbari et al.21 It is therefore rea-
sonable to assume that the prognostic value of the DFI on
OS following curative surgery for CRLM is more restricted
than previously thought. Since the evolution of surgical
treatment for CRLM, the factors on which clinical predic-
tions are made have remained largely unchanged. Studies
like this emphasize the limitations of predicting OS out-
comes in (colorectal) cancer patients based solely on clinical
predictors. Efforts should be made to improve predictions of
survival outcomes, possibly by relying more on prediction
based on underlying biological factors. In (stage IV) CRC,
there is increasing evidence that prognosis and treatment
effect can be predicted by biological variables, such as
preoperative skeletal muscle mass,33 the histopathological
growth pattern of CRLM,34–40 mutational status,41–44 and
the quantification of immune infiltration at the tumor
microenvironment,45–47 among others.
TABLE 3 Point estimates for the DFI of multivariable Cox regression models for overall and disease-free survival
Disease-free interval Overall survival [HR (95% CI)] Disease-free survival [HR (95% CI)]
0 versus 12 months 1.111 (0.928–1.330) 1.284 (1.114–1.480)
0 versus 24 months 1.202 (0.933–1.550) 1.444 (1.180–1.766)
0 versus 36 months 1.270 (0.980–1.647) 1.431 (1.164–1.758)
0 versus 48 months 1.330 (0.984–1.799) 1.356 (1.070–1.720)
DFI disease-free interval, HR hazard ratio, CI confidence interval
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CONCLUSION
Following surgical treatment of CRLM, the DFI is of
prognostic value for predicting disease recurrence, but not
for predicting OS outcomes. In an effort to improve clinical
prediction and decision making in patients with CRLM,
prognostic models need to be based more on underlying
biology rather than relying solely on clinical factors such as
the DFI.
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